Open AccessThe efficacy of sorafenib in preventing hepatocellular carcinoma recurrence after resection: a systematic review and meta-analysis
Author(s) -
Li Zhao,
Jie Gao,
Sheng Min Zheng,
Yan Wang,
Xiao Xiang,
Cheng Qian,
Jin Liang Zhu
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6458/2019
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , meta analysis , resection , carcinoma , oncology , general surgery , surgery
hepatocellular carcinoma (HCC) recurrence after liver resection remains a major threat for patients' survival. Sorafenib is recommended as an adjuvant treatment for patients after a liver resection. The objective of this meta-analysis was to estimate the therapeutic value of sorafenib in patients who underwent a HCC resection.